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Abstract 
Objectives: To examine short-term primary causes of death after percutaneous coronary 
intervention (PCI) in a national cohort before and during COVID-19.  
 
Background: Public reporting of PCI outcomes is a performance metric and a requirement in 
many healthcare systems. There are inconsistent data on the causes of death after PCI, and 
what proportion of these are attributable to cardiac causes. 
 
Methods: All patients undergoing PCI in England between 1st January 2017 and 10th May 
2020 were retrospectively analysed (n=273,141), according to their outcome from the date of 
PCI; no death and in-hospital, post-discharge, and 30-day death.  
 
Results: The overall rates of in-hospital and 30-day death were 1.9% and 2.8%, respectively. 
The rate of 30-day death declined between 2017 (2.9%) and February 2020 (2.5%), mainly 
due to lower in-hospital death (2.1% vs. 1.5%), before rising again from 1st March 2020 
(3.2%) due to higher rates of post-discharge mortality. Only 59.6% of 30-day deaths were 
due to cardiac causes, the most common being acute coronary syndrome, cardiogenic shock 
and heart failure, and this persisted throughout the study period. 10.4% of 30-day deaths after 
1st March 2020 were due to confirmed COVID-19.  
 
Conclusions: In this nationwide study, we show that 40% of 30-day deaths are due to non-
cardiac causes. Non-cardiac deaths have increased even more from the start of the COVID-19 
pandemic, with one in ten deaths from March 2020 being COVID-19 related. These findings 
raise a question of whether public reporting of PCI outcomes should be cause-specific.  
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Introduction 
Percutaneous coronary intervention (PCI) is the most common modality for coronary 
revascularization worldwide. (1,2) Advances in PCI techniques, stent platforms and operator 
experience have all led to a reduction in mortality following PCI in recent years. (3) (4) (5) 
Mortality post-PCI may be attributed to both cardiovascular (CV) causes and non-CV causes,  
although PCI mortality risk prediction models are focused on overall mortality. (6) (7) (8) 
This is particularly relevant in the context of public reporting of operator PCI outcomes, 
which is often perceived as a surrogate of operator skill and quality of health care provided, 
(9,10) even though 30-day mortality post PCI may not be directly related to the procedure. 
There are inconsistent findings amongst current data on the causes of death following PCI, 
with some studies suggesting that the majority of short-term mortality after PCI is CV in 
origin, while others showing that CV mortality represents a minority of all deaths. (7,11-13) 
However, the evidence to date is based on single or multicenter registry analyses, older 
procedural cohorts (e.g. pre 2010) and analyses from highly selected patient-groups (e.g. 
randomized controlled trials (RCTs)) that may not be generalizable to a contemporary PCI 
population. For example, a study of 115,191 patients undergoing PCI in the Veterans Affairs 
(VA) healthcare system showed that only a minority of deaths within 30 days were cardiac in 
origin (28%). (12) However, they analyzed a selected cohort comprising elderly males 
(median age 71 years, 99% males) that is not representative of national PCI practice across 
different healthcare systems. In contrast, an analysis of 21 RCT’s, CV mortality was at least 
5-fold higher than non-CV mortality (0.5% vs. 0.1%) at 30 days. (7) 
Data around changes in the cause of death from an all-comer national perspective 
following PCI are limited, particularly around the COVID-19 pandemic, that has infected 
more than 10 million patients worldwide, with the United Kingdom (UK) ranking second 
globally in terms of mortality.(14) Recent studies have demonstrated higher COVID-19 
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related mortality in patients with CV disease.(15-17) The underlying mechanisms behind 
increased COVID-19 mortality in patients with CV disease remain unclear, with possible 
explanations including factors such as advanced age, lower angiotensin converting enzyme 
(ACE)-2 levels and impaired immunity.(18) Little is known about the characteristics, as well 
as rates and causes of death, of patients undergoing PCI in the current COVID era, and how 
these compare to those before the pandemic. The present study was designed to examine 
national-level trends and causes of death, up to 30-days post-procedure, in a contemporary 
PCI cohort in England before and during the COVID-19 pandemic.  
Methods 
Data Source, Study Design and Population 
 All adults (aged ≥18 years) undergoing PCI between 1st January 2017 and 10th May 
2020 in England were retrospectively analyzed from the British Cardiovascular Intervention 
Society (BCIS) registry, stratified by outcome into 4 groups according to outcome from the 
date of PCI: no death, in-hospital death, up to 30-day death post-discharge (excluding in-
hospital death), and 30-day total death. There were no specified inclusion or exclusion 
criteria except missing data on death (299 cases), deaths occurring more than 30 days after 
PCI (n=12,220), multiple PCI procedures for the same patient (n=13,693), in which case only 
the final procedure was included with all other previous procedures excluded (flow diagram: 
Supplementary Figure 1). The BCIS registry comprises clinical, procedural and in-hospital 
outcome data for all procedures undertaken in the United Kingdom. (19,20) Mortality beyond 
the in-hospital phase was collected via record linkage with the Office for National Statistics 
(ONS) Civil Registrations of Death dataset (up to date as of 9th June 2020). (21) The process 
of death certification and registration is a legal requirement in the United Kingdom where a 
doctor who has seen the deceased within the last 14 days of life must complete a Medical 
Cause of Death Certificate unless a post-mortem examination is planned. International 
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Classification of Diseases, tenth revision (ICD-10) codes were used to extract data on the 
most prevalent primary causes of deaths (first line on the death certificate), including 
COVID-19, from the ONS Civil Registrations of Death dataset. A full list of the diagnosis 
codes used in the study is provided in Supplementary Table 1. Cardiac deaths included any 
death due to the following: ACS, heart failure, cardiogenic shock, cardiac arrest, pre-existing 
IHD and cardiac procedural complications.  
Outcomes 
 The main outcome was post-PCI death at specific time points: in-hospital, up to 30 
days post-discharge, and 30-day total, stratified in to cardiac, non-cardiac and COVID-19 
related.  
Statistical Analysis 
For exploratory analysis, we examined patient and procedural characteristics of 
patients undergoing PCI according to their final outcome: no death, in-hospital death, up to 
30-days post-discharge death and 30-day total death. Further comparisons were performed 
according to individual year, as well as pre- and post-COVID-19 pandemic in 2020 
(procedures performed between 1st January-29th February, and 1st March-10th May, 
respectively), and clinical syndrome (stable angina vs. ACS).  Age was normally distributed 
and, therefore summarized using mean and standard deviation (SD) and compared using the 
t-test. Categorical variables were summarized as percentages and analyzed using the chi 
squared (X2) test or Fisher’s exact test, where appropriate, and using the Kruskal-Wallis test 
for ordinal variables. Statistical analyses were performed using Stata 16 MP (College Station, 
TX). Multivariable logistic regression models were performed to examine predictors of 
cardiac, non-cardiac and COVID-related deaths, adjusting for the patient characteristics and 
procedural characteristics (only for cardiac and non-cardiac deaths) summarized in Appendix 
A, and are expressed as odds ratios (OR) with corresponding 95% confidence intervals (CI). 
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Multiple imputation with chained equations was performed for variables with missing data 
prior to model fitting, with a total of 10 imputations. Model estimates were later combined 
using Rubin’s rules.(22) The frequency of missing data prior to imputation is provided in 
Supplementary Table 2.  
Ethical Approval 
The UK Secretary of State for Health and Social Care has issued a time limited Notice 
under Regulation 3(4) of the NHS (Control of Patient Information Regulations) 2002 (COPI) 
to share confidential patient information. The study complies with the Declaration of 
Helsinki. This work was part of a work stream endorsed by the Scientific Advisory Group for 
Emergencies (SAGE), the body responsible for ensuring timely and coordinated scientific 
advice is made available to UK government decision makers. SAGE supports UK cross-
government decisions in the Cabinet Office Briefing Room (COBR)) and by NHS England, 
which overseas commissioning decisions in the NHS, and NHS Improvement, which is 
responsible for overseeing quality of care in NHS hospitals. 
Results 
  A total of 273,141 patients underwent PCI between 1st January 2017 and 10th May 
2020. Overall, procedural volumes were similar between 2017 to 2019 (~83,000/year). The 
number of procedures per 100,000 population sharply declined between 1st March 2020 to 
10th May 2020 compared with the same period in previous years (Figure 1) but was largely 
similar in January and February across all years.   
i. 30-day death rates 
The rate of 30-day death in the overall cohort was 2.8% (n=7,553), the majority of 
which occurred in hospital (1.9%, n=5,258). The rate of 30-day death declined between 2017 
and February 2020 (2.9% to 2.5%, p<0.001), primarily driven by lower in-hospital death (2.1 
vs. 1.5%), before rising again between 1st March 2020 and 10th May 2020 (3.2%) due to 
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higher rates of post-discharge mortality up to 30 days. (Figure 2A) Overall, both in-hospital 
cardiac and non-cardiac death rates both declined over the study period (2017 to May 2020: 
cardiac: 1.21% vs. 1.00%; non-cardiac: 0.91% vs. 0.79%). Overall 59.7% (n=4,499) of 30-
day deaths were due to cardiac causes. While 30-day cardiac and non-cardiac death rates both 
dropped between 2017 and February 2020, they were significantly increased in patients 
undergoing PCI between 1st March and 10th May 2020. (Figure 2B) 
ii. Patient and procedural characteristics 
 Overall, patients who died in-hospital or at 30-days were older (57 vs. 51 years), less 
likely to be males or from ethnic minorities, and more likely to have an ACS indication for 
their PCI. They had a greater prevalence of cardiovascular risk factors including previous 
coronary artery bypass grafts (CABG), diabetes, renal failure, moderate-poor left ventricular 
(LV) function, peripheral vascular disease (PVD) and previous cerebrovascular accidents 
(CVA). (Table 1) Furthermore, patients who died in-hospital and at 30-days were 
significantly more likely to have been in cardiogenic shock or suffered cardiac arrest or 
received mechanical ventilation prior to PCI. While this pattern of findings was consistent 
across the study years, patients undergoing PCI in 2020, particularly between March and 
May, were significantly younger (41-47 years vs. 51-57 years). (Table 2) 
 In terms of procedural characteristics, patients who died in-hospital or at 30-days 
were more likely to undergo a procedure via femoral access (34.8-47.2% vs. 19.2%), for 
grafts (35.5-37% vs. 29.6%) and multi-vessel disease (mean: 1.28-1.33 vs. 1.15) as well as 
multiple lesions (mean:: 1.41-1.46 vs. 1.25), using a greater number of drug eluting stents 
(DES; mean: 1.36-1.38 vs. 1.26) compared with those who did not die. (Table 1) 
Furthermore, they were less likely to undergo intravascular ultrasound (IVUS; 8.1-14.2% vs. 
23.5%) and fractional flow reserve assessment (FFR’ 7.7-8.4% vs. 10.4%), and more likely to 
receive glycoprotein 2b/3a inhibitors (22.7-33.3% vs. 12.3%). Patients who died within 30 
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days were also more likely to receive ticagrelor (27.2-29.7% vs. 23.9%), but no difference in 
the utilization of prasugrel was observed between groups. These findings persisted 
throughout the study period (Table 2).  
iii. 30-day causes of death 
 One in ten deaths (10.4%) at 30 days were due do confirmed COVID in those who 
underwent PCI between 1st March and 10th May 2020. (Table 3A) Overall, the majority of 
deaths within 30 days were cardiovascular in origin (59.6%, n=4,499), and this persisted 
between 2017 and 2020. (Figure 3) Cardiac deaths were mostly due to ACS (33.2%) and 
cardiogenic shock (10.2%), more so for in-hospital deaths than post-discharges, followed by 
heart failure (7.5%) which was higher in post-discharge than in-hospital deaths. (30-day 
death illustrated in Figure 4) While this pattern was consistent over the study period, the rate 
of in-hospital death due to cardiogenic shock significantly increased between 1st March and 
10th May 2020 (17.6% vs. 9.4-12.8%). (Table 3B) The most common causes of non-cardiac 
death were hypoxic brain injury for in-hospital death (10.9%) and non-COVID infections for 
post-discharge death (4.2%). (Table 3A) Deaths due to infections (non-COVID) increased in 
2020, both in-hospital and post-discharge, whereas deaths due to hypoxic brain injury 
declined over the same period, particularly post-discharge. (Table 3B) 
 When stratified by PCI indication, the majority of 30-day deaths occurred in patients 
who underwent PCI for ACS (n=7,205; 95.4% of all deaths). Within this group, the most 
common cause of 30-day death was cardiac in origin (60.2%), with a third of deaths primarily 
due to ACS (33.9%). Hypoxic brain injury and cardiogenic shock were the most prevalent 
other causes (11.3% and 10.6%, respectively), all of which were more likely to contribute to 
in-hospital than post-discharge death. (Supplementary Table 3) In patients who underwent 
PCI for stable angina, the most common causes of 30-day death were non-cardiac (53.6%). 
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The most common cardiac causes of 30-day death in the stable angina group were ACS 
(17.2%), heart failure (14.1%) and pre-existing heart disease (8.6%).  
iv. Predictors of death 
 Several factors correlated with increased odds of both 30-day cardiac and non-
cardiac, including advanced age (>50 years), ACS compared with stable angina 
(STEMI>NSTEACS), adverse events prior to PCI including cardiogenic shock, out-of-
hospital cardiac arrest and need for pre- PCI mechanical ventilation, renal failure, moderate-
poor left ventricular function, PVD, diabetes mellitus and history of MI or CVA. (Table 4) 
Amongst the procedural characteristics, the odds of 30-day cardiac death were increased with 
femoral access (OR 1.62 95% CI 1.47, 1.77), graft PCI (OR 1.24 95% CI 1.16, 1.32) and 
greater number of lesions (per additional lesion: OR 1.15 95% CI 1.06, 1.23) or vessels (per 
additional vessel: OR 1.34 95% CI 1.23, 1.46) (p<0.001 for all).  In contrast, the odds of 30-
day cardiac and non-cardiac death were lower amongst males (OR 0.70 95% CI 0.66, 0.75 
and 0.77 95% CI 0.72, 0.83, respectively, p<0.001 for both) and non-white ethnic 
backgrounds. (Table 4) Furthermore, the odds of 30-day cardiac death were reduced with 
radial access (OR 0.78 95% CI 0.70, 0.86) and the use of IVUS (OR 0.75 95% CI 0.67, 0.83), 
FFR (OR 0.81 95% CI 0.72, 0.91) and DES (OR 0.78 95% CI 0.68, 0.89) (p<0.001 for all). 
The odds of COVID-related 30-day death were significantly increased in patients aged 60-69 
years (OR 5.61 95% CI 2.07, 15.16, p=0.001) and those with renal failure (OR 7.31 95% CI 
2.66, 20.06, p<0.001). Although there was a trend towards increased COVID-related death 
amongst Black and Asian ethnicities (OR 2.95 95% CI 0.98, 8.84 and 1.70 95% CI 0.55, 
5.26, respectively) and males (OR 1.59 95% CI 0.60, 4.23), this was not statistically 
significant, possibly due to the relatively small number of COVID-19 deaths.  
Discussion 
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 The present study highlights several important findings from a contemporary 
nationwide cohort of patients treated by PCI in England. First, we find that only two of every 
three deaths at 30-days following PCI were from cardiac causes, and that this has persisted 
throughout the study period, even during the COVID-19 pandemic. Patients treated for an 
ACS accounted for a third of 30-day deaths throughout the study, followed by hypoxic brain 
injury and cardiogenic shock as the most prevalent causes. Second, we observe that in-
hospital and 30-day deaths after PCI, from both cardiac and non-cardiac causes, have 
declined in the past three years, although these have risen again after the start of the COVID-
19 pandemic (1st March through 10th May 2020), primarily due to non-cardiac deaths. One in 
ten deaths at 30 days were due to COVID-19 in patients undergoing PCI between March and 
May 2020.  
 Some previous studies have suggested that short-term mortality (≤30 days) after PCI 
is predominantly due to cardiac causes, while others have shown otherwise. (6,7,13) 
However, there are limited data on the causes of death after PCI in the current era, and how 
these have changed from a national perspective. Previous studies provided conflicting 
information, likely due to variations in the cohorts they had examined, which included 
individual centers (11) or healthcare systems (12), or only inpatient procedures, with no 
analysis of post-discharge causes of death.(5)  Pooled data from 21 RCTs demonstrated a 7-
fold higher rate of CV than non-CV deaths in 32,882 patients undergoing PCI (relative ratio: 
6.99, 95% CI 3.16–15.42). (7) Despite the added value of this study, patients enrolled in 
RCTs are highly selected cohorts that are often healthier than the background population 
encountered in daily practice. Furthermore, the authors mention that death of unknown cause 
in RCTs was adjudicated as CV in origin as per protocol, which may have influenced the 
external validity of their findings. In contrast, a study by Bricker et al. reports higher rates 
(~60%) of non-cardiovascular/undifferentiated deaths at 30-days in 115,191 patients 
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undergoing PCI in the VA healthcare system in the US. However, their study examined a 
selected cohort of veterans, who were predominantly males (99%) and generally older than 
the average population. (12) Furthermore, deaths that occurred outside the VA were not 
captured, which may explain their apparently high number of non-cardiac deaths. 
Although the majority of in-hospital and 30-day deaths in our cohort were cardiac in 
origin, 4 out of 10 deaths (~40%) were non-cardiac, with hypoxic brain injury and infections 
being the most common non-cardiac causes, a finding that persisted over the study period. 
This finding raises questions regarding the utility of currently used PCI mortality risk scores, 
such as the New York State Risk (NYSR) score and National Cardiovascular Data Registry 
(NCDR) score. (6,8,23) While these scores have been validated for the prediction of overall 
in-hospital mortality, they do not discriminate between CV and non-CV deaths, with the 
latter representing a significant proportion of all in-hospital deaths. Furthermore, these risk 
scores were derived from relatively outdated cohorts (e.g. NCDR: 2004 to 2006; NYSR: 
2009 to 2010), whose procedural characteristics are different to the current era. Similarly, an 
argument could be made that public reporting of operator outcomes should detail the broad 
nature of the cause of death, particularly in view of the cause of death distribution during the 
COVID-19 pandemic, where one in ten deaths at 30-days were due to COVID-19. 
Interestingly, most of the COVID-19 deaths in our cohort were amongst patients undergoing 
PCI for stable angina, although it does not determine whether the transmission of COVID-19 
was nosocomial or post discharge in the community. Nevertheless, this raises a concern 
regarding the safety of performing non-emergent PCI until the pandemic has subsided.  
There are limited data regarding trends in in-hospital and 30-day mortality in recent 
years. In a single-center study of 19,506 patients undergoing PCI in Mayo Clinic (Rochester, 
Minnesota), Spoon and colleagues reported a decline in in-hospital death rates between 1991 
(2.7%) and 2006 (2.2%), as well as a reduction in long-term (5-year) cardiac death (33% 
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temporal decline), with a parallel increased in long-term non-cardiac death (57%).(11) Their 
findings, however, were derived from a relatively old cohort that was less likely to receive 
DES and newer P2Y12 inhibitors, and one that was managed in a large tertiary facility and, 
thereby, does not reflect contemporary national-level practices or outcomes. Furthermore, 
their analysis does not provide information on the cause of in-hospital mortality (e.g. cardiac 
vs. non-cardiac), and only considered this aspect for long-term outcomes. In contrast, 
Alkhouli et al. reported an increase in in-hospital mortality after PCI between 2003 and 2016, 
both in ACS and stable angina patients, in a 20% stratified national sample of US 
hospitalizations.(5) While their analysis provides us with insights in to the trends of in-
hospital mortality in inpatients undergoing PCI, it does not inform us on outcomes for 
outpatient procedures, which represent a large proportion of all PCI cases. Moreover, they 
did not report the cause of in-hospital mortality. Our findings suggest that both 30-day 
cardiac and non-cardiac death rates after PCI have declined over the past 3 years, mainly 
driven by a fall in in-hospital death, up until the start of the COVID-19 pandemic (1st March 
2020), after which there was an increase in both in-hospital cardiac and non-cardiac deaths. 
The latter could be explained by baseline differences between patients undergoing PCI before 
and after the pandemic. For example, patients undergoing PCI during the pandemic could 
have been more critically unwell, or higher-risk PCI cases, although we note that patient and 
procedural characteristics during both time periods were relatively similar. Another possible 
explanation is the delayed presentation of ACS cases during the pandemic, which have been 
widely reported in recent literature, as well as less optimal care for critically ill cases due to 
pressures on hospital systems as a result of the COVID-19 pandemic. (24,25) (26)   
Strengths and Limitations 
  The present study is the largest to report trends of 30-day causes of deaths after PCI in 
a contemporary nationwide cohort, including both inpatient and outpatient procedures, 
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making it generalizable to the wider population of interest. Another notable strength is our 
ascertainment and determination of cause of death, which is based on linkage to the ONS 
database and details from the Medical Cause of Death Certificate, unlike some previous 
studies. However, there are several limitations to the present study. First, whilst the BCIS 
dataset captures cardiovascular risk factors and procedural characteristics, it does not capture 
measures of comorbidity, such as Charlson or Elixhauser scores, or frailty that are important 
determinants of mortality post PCI. (27,28) The observational nature of our study means that 
residual unmeasured confounders such as these and others may not be accounted for. Third, 
given that these data are the most contemporary available (census June 2020 for procedures 
in May 2020) there is insufficient follow up to study longer term causes of death, particularly 
given that it has been shown in patients derived from RCTs that non- cardiovascular causes 
of mortality become more important at longer term follow up.(7) Finally, COVID-19 cases 
were identified according to the corresponding ICD-10 code (U07.1 – confirmed COVID). 
However, the data does not inform us of whether this confirmation was based on virology/ 
serology or clinical diagnoses.  
Conclusions 
 In a nationwide cohort of PCI procedures, we demonstrate that a significant 
proportion of 30-day deaths is due to non-cardiac causes, a finding that has persisted over the 
past 3 years. Overall, in-hospital and 30-day cardiac and non-cardiac deaths have declined 
over 3 years, before increasing again during the COVID-19 pandemic. One in ten deaths in 
those undergoing PCI from 1st March 2020 were due to COVID-19. The present findings 
highlight that overall 30-day mortality may not be a reliable measure of performance in the 
context of PCI, and drive the need for other objective measures, which may include cause-
specific mortality.   
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Figures captions and legends: 
Figure 1. Trends of procedural volumes per 100,000 population over the study period 
Legend: *Procedures until 10th May 2020, ptrend=non-significant for January-February, ptrend 
<0.001 for March to May 
Figure 2. Trends of A) overall death and B) cardiac and non-cardiac death over the study 
period 
Legend: *May procedures until 10th May 2020 
 
Figure 3. Figure 3. Trends of 30-day causes of death over the study period 
Figure 4. Figure 4. Causes of 30-day mortality in A)2017-2019, B) January-February 2020 
and C) March-May 2020* 
Legend: *Correct as of 9th June 2020
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Table 1. Patient and procedural characteristics of the total cohort 
 
No Death 
(n=265,588) 
In-hospital 
death 
(n=5,258) 
Discharge up 
to 30 days 
(n=2,295) 
30-day death 
(n=7,553) 
Patient characteristics 
Age, mean (SD) 51 (12) 57 (13) 57 (12) 57 (13) 
Age Categories (years), %     
<50 47.6 29.2 28.3 28.9 
50-59  27.0 24.5 24.2 24.4 
60-69  20.7 30.4 31.6 30.8 
≥70 4.8 16.0 15.9 15.9 
Males, % 74.5 67.8 71.1 68.8 
Ethnicity, % 
 
  
 
White 81.9 84.5 83.9 84.7 
Black 4.7 4.1 4.9 3.9 
Asian 7.7 7.7 6.4 7.3 
Other 5.7 3.8 4.8 4.1 
Clinical Indication, %     
Stable angina 36.8 2.8 9.1 4.6 
NSTEACS 37.8 22.7 37.7 27.3 
STEMI 25.5 74.5 53.2 68.1 
Previous MI, % 26.5 22.6 27.6 24.3 
Previous PCI, % 29.1 17.0 20.8 18.2 
Previous CABG, % 33.7 40.0 39.7 5.9 
Diabetes Mellitus, % 23.4 29.6 31.0 29.6 
Renal Failure, % 1.8 9.6 8.8 9.3 
LV function, %* 
 
  
 
Good 68.4 18.0 27.5 22.0 
Moderate 29.0 60.4 58.7 58.8 
Poor 2.5 21.6 13.8 19.2 
Hypercholesterolaemia, % 71.0 64.5 65.1 64.8 
Peripheral Vascular Disease, 
% 5.5 14.8 12.3 14.0 
Previous CVA, % 4.1 8.5 8.3 8.3 
Hypertension, % 56.1 51.0 51.4 51.2 
Current/Previous smoker, % 57.9 54.1 56.1 54.7 
Cardiogenic Shock (pre-
procedure), % 1.6 49.2 20.8 40.6 
Out of hospital cardiac arrest, 
% 2.2 35.4 19.6 30.3 
Procedural characteristics and in-hospital medications  
Mechanical Ventilation, % 0.7 25.3 11.6 21.2 
Access route*     
Radial, % 89.9 65.5 77.1 68.9 
Femoral, % 19.2 47.2 34.8 43.6 
No. of vessels, mean (SD) 1.15±0.59 1.33±0.62 1.28±0.62 1.31±0.62 
No. of lesions, mean (SD) 1.26±0.75 1.46±0.77 1.41±0.78 1.45±0.78 
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No. of drug eluting stents, 
mean (SD) 1.26±0.96 1.38±1.10 1.36±1.07 1.37±1.09 
Fractional Flow Reserve, % 10.4 7.7 8.4 7.9 
Intravascular ultrasound, % 23.5 8.1 14.2 9.9 
Grafts, % 29.6 37.0 35.5 36.5 
Ticagrelor, % 23.9 29.7 27.2 29.3 
Prasugrel, % 4.9 5.0 4.7 4.9 
Glycoprotein 2b/3a inhibitor, 
% 12.3 33.3 22.7 30.1 
*overlap between access routes in some cases; SD: standard deviation 
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Table 2. Patient and procedural characteristics of study groups according to year 
 
2017-2019 
(n=251,304) 
Jan-Feb 2020 
(n=12,774) 
Mar-May 2020 
(n=9,063) 
 
No Death In-hospital 
Discharg
e to 30-
days 
30-day 
total 
No 
Death 
In-
hospital 
Discharg
e to 30-
days 
30-day 
total 
No 
Death 
In-
hospital 
Discharg
e to 30-
days 
30-day 
total 
Number (% within group) 244353 (97.2) 
4915 
(2.0) 
2036 
(0.8) 
6951 
(2.8) 
12458 
(97.5) 
184 
(1.5) 
132 
(1.1) 
316 
(2.6) 
8777 
(96.8) 
159 
(1.8) 
127 
(1.4) 
286 
(3.2) 
Patient characteristics 
Age 51 (12) 57 (13) 57 (12) 57 (13) 41 (12) 47 (12) 47 (11) 47 (12) 40 (12) 46 (11) 46 (12) 46 (11) 
Males, % 74.4 67.7 70.9 68.6 74.5 65.8 72.7 68.7 75.2 73.6 73.2 73.8 
Ethnicity, %             
White 81.8 84.8 84.7 84.8 82.2 85.3 78.8 84.2 82.8 83.6 82.7 83.6 
Black 4.8 3.8 4.3 3.9 5.1 2.7 6.8 2.8 4.6 4.4 6.3 4.9 
Asian 7.7 7.6 6.2 7.2 7.7 7.6 9.1 8.2 7.7 8.8 6.3 7.7 
Other 5.8 3.8 4.8 4.1 4.9 4.3 5.3 4.7 5.0 3.1 4.7 3.8 
Clinical Indication, %             
Stable angina 37.1 2.6 9.3 4.5 36.1 4.3 6.8 5.1 28.7 3.1 9.4 5.6 
NSTEACS 37.6 23.1 37.4 27.2 38.4 20.7 38.6 28.2 41.8 14.5 42.5 26.9 
STEMI 25.3 74.4 53.3 68.2 25.4 75.0 54.5 66.8 29.5 82.4 48.0 67.5 
Previous MI, % 26.6 23.2 27.5 24.4 26.3 17.9 29.5 23.1 24.7 17.0 28.3 22.0 
Previous PCI, % 29.0 17.2 20.4 18.2 30.4 15.2 25.8 19.6 27.7 15.1 22.0 18.5 
Previous CABG, % 6.7 5.4 7.1 5.9 33.9 45.7 43.2 6.3 33.2 39.0 38.6 4.5 
Diabetes Mellitus, % 23.3 29.0 30.6 29.5 24.7 29.3 28.8 28.8 24.0 30.8 29.9 32.2 
Renal Failure, % 1.8 9.5 8.7 9.3 2.2 9.3 7.4 7.6 2.0 8.1 13.3 11.2 
LV function, %*             
Good 68.6 18.5 29.7 21.8 68.5 19.0 18.2 22.5 65.9 17.6 35.4 25.5 
Moderate 28.9 59.9 56.1 58.8 28.7 58.2 69.7 59.2 31.5 61.6 55.1 58.7 
Poor 2.5 21.6 14.1 19.4 2.7 22.8 12.1 18.4 2.7 20.8 9.4 15.7 
All rights reserved. No reuse allowed without perm
ission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprint
this version posted July 27, 2020. 
.
https://doi.org/10.1101/2020.07.18.20155549
doi: 
m
edRxiv preprint 
  
Hypercholesterolaemia, % 71.0 64.9 64.1 64.7 70.9 62.0 72.0 64.9 69.3 62.9 72.4 67.8 
Peripheral Vascular 
Disease, % 5.5 14.9 12.1 14.1 5.8 14.1 15.9 13.9 5.4 13.2 10.2 11.9 
Previous CVA, % 4.4 8.6 8.7 8.6 1.5 4.9 4.5 3.8 1.5 4.4 3.9 4.2 
Hypertension, % 56.1 51.1 50.8 51.0 57.0 51.6 56.1 52.2 55.6 49.7 59.8 54.2 
Previous/current smoker, 
% 58.0 54.3 56.4 54.9 56.8 52.2 50.0 51.3 56.0 50.3 58.3 53.8 
Cardiogenic Shock (pre-
procedure), % 1.6 49.3 20.7 40.9 1.6 41.8 23.5 34.2 1.7 54.1 20.5 39.2 
Out of hospital cardiac 
arrest, % 2.2 35.5 19.1 30.7 2.1 32.6 20.5 28.5 2.0 30.2 14.2 22.7 
Procedural characteristics and in-hospital medications 
Mechanical Ventilation, % 0.7 25.4 11.7 21.4 0.8 23.9 12.9 19.3 0.6 26.4 7.9 18.2 
Access route*             
Radial, % 89.7 65.0 77.2 68.6 91.2 69.0 75.0 71.2 92.1 74.2 74.8 74.1 
Femoral, % 19.3 48.2 35.4 44.5 19.6 37.5 36.4 37.3 17.9 31.4 27.6 30.1 
No. of vessels, mean (SD) 1.14±0.59 
1.33±0.6
2 
1.27±0.6
2 
1.31±0.6
2 
1.14±0.5
9 
1.28±0.5
7 
1.25±0.5
9 
1.27±0.5
8 
1.19±0.6
1 
1.31±0.6
2 
1.35±0.7
0 
1.33±0.6
5 
No. of lesions, mean (SD) 1.26±0.75 
1.47±0.7
7 
1.42±0.7
9 
1.45±0.7
9 
1.23±0.7
3 
1.41±0.7
3 
1.33±0.7
6 
1.38±0.7
4 
1.31±0.7
6 
1.43±0.7
7 
1.48±0.8
1 
1.45±0.7
8 
No. of drug eluting stents, 
mean (SD) 
1.26±0.9
6 
1.39±1.1
0 
1.37±1.0
9 
1.38±1.1
0 
1.19±0.9
2 
1.23±1.0
7 
1.25±0.9
9 
1.25±1.0
4 
1.26±0.9
5 
1.27±1.0
3 
1.39±0.9
8 
1.32±1.0
1 
Fractional Flow Reserve, % 10.4 7.5 8.6 7.9 10.1 9.2 9.1 9.8 10.0 10.1 3.1 6.6 
Intravascular ultrasound, 
% 23.4 7.9 14.3 9.8 26.9 10.3 15.2 12.3 22.9 11.9 11.0 11.5 
Grafts, % 29.8 36.8 35.2 36.4 29.7 41.3 40.2 41.1 30.0 38.4 32.3 35.0 
Ticagrelor, % 24.9 30.6 29.2 30.2 12.1 22.8 15.2 21.5 12.1 14.5 13.4 14.7 
Prasugrel, % 5.1 5.2 4.6 5.0 2.0 3.8 3.0 2.2 2.1 1.9 3.1 5.9 
Glycoprotein 2b/3a 
inhibitor, % 12.2 33.2 22.9 30.2 11.9 32.1 23.5 28.5 13.6 37.1 19.7 29.4 
*overlap between access routes in some cases; SD: standard deviation
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Table 3A. In-hospital and 30-day primary cause of death for the total cohort 
 
In-hospital 
death 
(n=5,258) 
Discharge to 
30 days 
(n=2,295) 
30-day death 
(n=7,553) 
COVID-19, %* 0.01 10.4 5.2 
Cardiac    
Pre-existing IHD, % 1.6 6.3 3.0 
ACS, % 34.8 29.5 33.2 
Heart failure, % 6.3 10.2 7.5 
Cardiogenic shock, % 12.3 5.6 10.2 
Cardiac arrest, % 3.1 2.8 3.0 
Cardiac procedural complications, % 2.9 3.0 3.0 
Non-Cardiac    
Infections, % 2.7 7.5 4.2 
Acute respiratory conditions, % 0.4 0.5 0.4 
Cancers, % 0.3 1.8 0.8 
Stroke, % 1.2 3.0 1.7 
AKI, % 0.2 0.6 0.3 
CKD, % 0.0 0.2 0.1 
Major bleeding, % 0.4 0.7 0.5 
Non-cardiac procedural complications, 
% 1.5 1.1 1.4 
Hypoxic Brain injury, % 12.2 8.1 10.9 
Other causes, % 20.9 18.1 20.1 
*Rate is only based on procedures in 2020 only 
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Table 3B. In-hospital and 30-day primary cause of death according to year 
 
2017-2019 
(n=6,951) 
Jan-Feb 2020 
(n=316) 
Mar-May 2020 
(n=286) 
 
In-hospital 
(n=4915) 
Dischar
ge to 30-
days 
(n=2036) 
30-day 
total 
In-hospital 
(n=184) 
Dischar
ge to 30-
days 
(n=132) 
30-day 
total 
In-hospital 
(n=159) 
Discharg
e to 30-
days 
(n=127) 
30-day 
total 
COVID-19, % - - - 0.0 1.5 0.01 2.0 19.7 10.2 
Cardiac          
Pre-existing IHD, % 1.5 6.5 3.0 0.5 5.3 2.5 0.0 1.6 0.7 
ACS, % 34.2 29.3 32.7 41.3 32.6 37.7 32.7 35.4 33.9 
Heart failure, % 6.3 10.4 7.5 5.4 8.3 6.7 6.9 7.9 7.3 
Cardiogenic shock, % 12.8 5.9 10.7 9.4 12.1 10.6 17.6 4.7 11.6 
Cardiac arrest, % 2.9 2.6 2.8 2.4 6.1 4.0 2.7 1.6 2.2 
Cardiac procedural 
complications, % 3.1 3.4 3.2 0.6 0.0 0.3 0.7 0.0 0.4 
Non-cardiac          
Infections, % 2.5 6.9 3.8 4.9 6.8 5.7 5.0 9.4 7.0 
Acute respiratory conditions, % 0.4 0.6 0.5 - - - 0.0 1.6 0.7 
Cancers, % 0.3 1.4 0.6 0.0 1.5 0.6 1.3 0.8 1.0 
Stroke, % 1.2 2.9 1.7 0.5 1.5 0.9 1.3 1.6 1.4 
AKI, % 0.1 0.9 0.4 - - - - - - 
Major bleeding, % 0.3 0.2 0.2 0.0 0.8 0.3 - - - 
Non-cardiac procedural 
complications, % 1.6 1.2 1.5 0 0 0 0 0 0 
Hypoxic Brain injury, % 12.3 8.5 11.2 10.6 8.3 9.6 10.8 1.6 6.6 
Other causes, % 20.7 18.5 20.1 26.0 15.2 21.5 21.4 14.2 18.2 
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Table 4. Predictors of in-hospital and 30-day cardiac, non-cardiac and COVID-related 
deaths  
Predictor/ 
Outcome 
30-day cardiac 30-day non-cardiac 30-day COVID 
OR (95% CI) p-
value OR (95% CI) 
p-
value OR (95% CI) 
p-
value 
Patient characteristics 
Age category 
(years)       
<50 (reference)       
50-59  1.98 [1.79, 2.19] <0.001 1.71 [1.54, 1.89] <0.001 1.73 [0.54, 5.52] 0.352 
60-69  3.44 [3.12, 3.79] <0.001 2.68 [2.42, 2.98] <0.001 5.61 [2.07, 15.16] 0.001 
≥70 7.36 [6.55, 8.27] <0.001 4.47 [3.90, 5.12] <0.001 3.39 [0.64, 17.92] 0.150 
Male 0.70 [0.66, 0.75] <0.001 0.77 [0.72, 0.83] <0.001 1.59 [0.60, 4.23] 0.353 
Race       
White (reference)       
Black 0.75 [0.63, 0.88] <0.001 0.87 [0.74, 1.02] 0.094 2.95 [0.98, 8.84] 0.054 
Asian 0.86 [0.76, 0.97] 0.016 0.86 [0.75, 0.98] 0.025 1.70 [0.55, 5.26] 0.355 
Other 0.82 [0.71, 0.96] 0.015 0.88 [0.75, 1.03] 0.099 0.74 [0.10, 5.64] 0.775 
Clinical 
Syndrome       
Stable angina 
(reference)       
NSTEACS 3.78 [3.30, 4.34] <0.001 3.17 [2.79, 3.61] <0.001 2.98 [0.97, 9.15] 0.056 
STEMI 7.45 [6.46, 8.58] <0.001 5.17 [4.51, 5.92] <0.001 2.32 [0.65, 8.24] 0.193 
Previous MI 1.19 [1.08, 1.30] <0.001 1.12 [1.01, 1.24] 0.026 0.82 [0.30, 2.22] 0.691 
Previous PCI 0.65 [0.58, 0.71] <0.001 0.73 [0.66, 0.81] <0.001 1.80 [0.70, 4.63] 0.222 
Previous CABG 0.80 [0.70, 0.92] 0.001 0.86 [0.75, 0.99] 0.033 1.28 [0.36, 4.58] 0.706 
Diabetes 
Mellitus 1.49 [1.39, 1.60] <0.001 1.39 [1.29, 1.50] <0.001 1.15 [0.51, 2.61] 0.739 
Renal Failure 3.77 [3.33, 4.25] <0.001 3.99 [3.52, 4.52] <0.001 7.31 [2.66, 20.06] <0.001 
LV Function       
Good (reference)       
Moderate 2.65 [2.46, 2.86] <0.001 2.37 [2.19, 2.55] <0.001 1.41 [0.64, 3.10] 0.397 
Poor 6.41 [5.77, 7.13] <0.001 5.12 [4.57, 5.74] <0.001 1.06 [0.13, 8.70] 0.957 
Hypercholestero
laemia 0.95 [0.86, 1.04] 0.230 0.96 [0.87, 1.05] 0.349 1.12 [0.32, 3.88] 0.862 
PVD 1.54 [1.38, 1.72] <0.001 1.50 [1.34, 1.68] <0.001 1.64 [0.49, 5.51] 0.420 
Previous CVA 1.37 [1.20, 1.55] <0.001 1.47 [1.28, 1.68] <0.001 3.50 [0.64, 19.18] 0.150 
Hypertension 1.16 [1.06, 1.26] 0.001 1.08 [0.98, 1.18] 0.116 1.73 [0.56, 5.40] 0.344 
Cardiogenic 
Shock (pre- 8.39 [7.75, 9.07] <0.001 5.23 [4.79, 5.71] <0.001 2.74 [0.51, 14.62] 0.238 
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operative) 
Out-of-hospital 
arrest 1.80 [1.60, 2.02] <0.001 3.06 [2.72, 3.43] <0.001 1.69 [0.25, 11.52] 0.590 
Ventilation in-
hospital 2.60 [2.25, 3.00] <0.001 3.45 [3.01, 3.95] <0.001 3.45 [0.25, 47.58] 0.354 
Medications and Procedural characteristics  
P2Y12 inhibitor 1.00 [0.97, 1.03] 0.918 0.98 [0.95, 1.01] 0.250 1.26 [0.82,1.94] 0.283 
Glycoprotein 
2b/3a inhibitor 0.92 [0.86, 1.00] 0.038 0.91 [0.84, 0.98] 0.017   
Radial access 0.78 [0.70, 0.86] <0.001     
Femoral access 1.62 [1.47, 1.77] <0.001     
No. of vessels 1.34 [1.23, 1.46] <0.001     
No. of lesions 1.15 [1.06, 1.23] <0.001     
FFR 0.81 [0.72, 0.91] <0.001     
IVUS 0.75 [0.67, 0.83] <0.001     
Drug eluting 
stents 0.78 [0.68, 0.89] <0.001     
Grafts 1.24 [1.16, 1.32] <0.001     
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